Invivyd’s bid to replace the Covid vaccine gets funding, though FDA approval still hangs over it
A small biotech firm's antibody rival to the vaccine holds promise, yet a bar set by the FDA may still stand before it.
CLAY TRIBUNE / THE ARCHIVE
Tag: biotech
In Shanghai’s ‘Science City,’ China’s Ascendant Biotechs Make Their Pitch to the World
Shanghai's 'Science City' biotechs pitch cheaper, faster drug trials against US rivals, citing a 11-month record.
AstraZeneca Invests $2 Billion in Summit Therapeutics as Four Deals Land Overnight
AstraZeneca invests $2 billion in Summit Therapeutics, Novo buys a Chinese obesity pill, and two biotech deals go the other way.
Enveda Raises $311M Series E to Advance Nature-Derived AI Drugs Through Clinical Trials
Enveda raises $311M to advance AI-discovered nature-derived drugs into clinical trials, valuing the biotech at $2B.
Novo Nordisk Names Five Multi-Blockbuster Targets and Promises Revenue Growth on Par With Big Pharma
Novo Nordisk promises five blockbuster drugs by 2030 and says it will sell medicines more like consumer goods.
IN8bio Hires LAVA Therapeutics’ Former CSO Oxana Polyakova as Senior VP of R&D
A newsletter tracking biotech hires posts but one name: Oxana Polyakova joins IN8bio, and the rest is silence.
Podcast Roundup: Visa Reprieve for Foreign Scientists and New Definium Psychedelic Data
A reprieve for foreign scientists, and new data from Definium Therapeutics in the psychedelics field, weigh upon the future of American research.
Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question
A rival drug's failure sent Amgen's share price tumbling, casting doubt upon the very hypothesis its own late-stage asset relies upon.
Ovid Therapeutics Hands Off Soticlestat to Fund Its Next Two Lead Programs
Ovid Therapeutics hands off soticlestat to fund OV4071 and OV329 pipeline, trading direct control for milestone payments.
Google’s AlphaGenome Atlas Predicts the Effect of Every Possible Single-Base Change in the Human Genome
Google's AlphaGenome Atlas predicts effects of all 9 billion possible single-base DNA changes, mapping non-coding genome function.